82211-92-5 Usage
Uses
Used in Pharmaceutical Drug Synthesis:
4-(2-CHLORO-PHENYL)-PIPERIDINE HYDROCHLORIDE is used as a key intermediate in the synthesis of pharmaceutical drugs. Its unique structure and properties make it a valuable building block for creating new medications and research compounds.
Used in Treating Neurological and Psychiatric Disorders:
In the medical field, 4-(2-CHLORO-PHENYL)-PIPERIDINE HYDROCHLORIDE is used as a potential therapeutic agent for treating various neurological and psychiatric disorders. Its specific chemical structure allows it to interact with biological targets, offering potential benefits in managing these conditions.
Used in Drug Discovery and Development:
4-(2-CHLORO-PHENYL)-PIPERIDINE HYDROCHLORIDE is employed as a crucial tool in drug discovery and development within the pharmaceutical industry. Its versatility and chemical properties facilitate the exploration of new drug candidates and the advancement of existing medications.
Check Digit Verification of cas no
The CAS Registry Mumber 82211-92-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,2,2,1 and 1 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 82211-92:
(7*8)+(6*2)+(5*2)+(4*1)+(3*1)+(2*9)+(1*2)=105
105 % 10 = 5
So 82211-92-5 is a valid CAS Registry Number.
InChI:InChI=1/C11H14ClN.ClH/c12-11-4-2-1-3-10(11)9-5-7-13-8-6-9;/h1-4,9,13H,5-8H2;1H
82211-92-5Relevant academic research and scientific papers
(4-PHENYL-PIPERIDIN-1-YL)-[5-1H-PYRAZOL-4YL)-THIOPHEN-3-YL]-METHANONE COMPOUNDS AND THEIR USE
-
Page/Page column 75, (2011/04/19)
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)- [5-(1 H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 1 1 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.
